NCT01266031

Phase 1/Phase 2Interventional

Trials that are a combination of phases 1 and 2.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jul 12, 2011
Primary completion: Jun 30, 2015
Completion date: Jan 31, 2017
First posted: —
Last posted: —
Enrollment: 96
Arms / groups: 2 / —
Source: AACT · pre-existing

Sponsors

National Cancer Institute (NCI)Lead sponsor
MerckCollaborator
Medical University of South CarolinaCollaborator
National Cancer Institute (NCI)Overall official - principal investigator
Henry Ford Health SystemCollaborator
Columbia UniversityCollaborator
University of Texas at HoustonCollaborator
Rush UniversityCollaborator
Brain Tumor Trials CollaborativeCollaborator
GenentechCollaborator
Northwestern UniversityCollaborator
Ohio State UniversityCollaborator
University of North Carolina at Chapel HillCollaborator
University of UtahCollaborator
Baylor UniversityCollaborator
University of FloridaCollaborator
University of WashingtonCollaborator
Washington University in St. LouisCollaborator
National Institutes of Health (NIH)Reponsible party - principal investigator
University of ChicagoCollaborator
University of RochesterCollaborator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.